iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 11.2% in November

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 230,900 shares, a drop of 11.2% from the October 31st total of 260,100 shares. Approximately 2.5% of the company’s stock are sold short. Based on an average trading volume of 128,000 shares, the days-to-cover ratio is currently 1.8 days.

iBio Stock Up 11.8 %

NYSEAMERICAN IBIO traded up $0.31 during trading on Friday, reaching $2.94. The company’s stock had a trading volume of 140,692 shares, compared to its average volume of 1,137,105. iBio has a 1-year low of $1.02 and a 1-year high of $4.98. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.